Presented by
IVBM Event Coverage
Oral Iberdomide May Widen Myeloma Access: Mateo Mejia Saldarriaga, MD
Weill Cornell's Mateo Mejia Saldarriaga, MD, explains why oral options like iberdomide and clinical trials matter in the immunotherapy era of myeloma.
UAB Works to Deliver Cutting-Edge Cancer Therapies, Reach Every Patient
UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.
Bridging Distance, Delivery Gaps in Cancer Care
Biomarker testing, treatment sequencing, drug delivery, and rural access barriers were examined during an IVBM event in Salt Lake City.
It’s the Best of Times and Worst of Times for Cancer Care in Tampa
More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
New Cancer Drugs Test the Limits of Care Delivery
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
Ethically Sound Care Starts Before the ICU: Nneka Sederstrom, PhD
Early goals-of-care talks, ethics consults, and upstream planning can help ICU teams deliver care that matches what patients actually want.
On-Body Isatuximab Eases Myeloma Care: Mateo Mejia Saldarriaga, MD
Weill Cornell's Mateo Mejia Saldarriaga, MD, discusses patient preference for on-body isatuximab and how to sequence CAR T and bispecifics in myeloma.
Oncologists Grapple With Sequencing, Access as Treatments Multiply
Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
Boston Experts Weigh Access, Sequencing, and Testing Across 4 Cancers
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
Oncology Experts Call for Less Toxic Care, Smarter Access
Experts tackled CAR T access, trial equity, and overtreatment in breast cancer at an AJMC Institute for Value-Based Medicine event in San Francisco.
Access and Innovation in North Carolina’s Research Triangle
North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
Overcoming Barriers to Precision Care and Patient Access
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
MRD-Guided Therapy Reshapes CLL Treatment, Despite Hurdles
Madhav R. Seshadri, MD, speaks on CLL's shift toward fixed-duration, MRD-guided regimens, MRD testing barriers, and open questions on drug sequencing.
Personalizing Relapsed Multiple Myeloma Therapy: Amandeep Godara, MBBS
Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
Removing Barriers to Rural Oncology Care: Christos Vaklavas, MD
Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.
Blood-Based Testing, Telehealth Help Close Biomarker Access Gaps
Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including for patients with non–small cell lung cancer.
Tailoring CAR T, Bispecific Use in Myeloma: Amandeep Godara, MBBS
The final part explores individualized CAR T and bispecific therapy selection in multiple myeloma and the need for stronger academic-community collaboration.
Resource Demands Challenge Community Oncology: Christos Vaklavas, MD
In part 2, Christos Vaklavas, MD, discusses clinical trial complexity and the shift toward more accessible treatment delivery.
CAR T Access Challenged by Geography, Cost, and Treatment Delays
Scheduling apheresis, manufacturing the cells, and ultimately administering the treatment can take several weeks, Madhav Seshadri, MD, explains.
Access, Logistics Shape Multiple Myeloma Immunotherapy Decisions
Amandeep Godara, MBBS, explained that rural patients with multiple myeloma face various barriers to immunotherapies that may delay treatment.
Distance, Telehealth Access Complicate Cancer Care in the Mountain West
Christos Vaklavas, MD, discusses geographic and telehealth barriers to cancer care access across Utah and the broader Mountain West.
Patient, Disease Factors Shape Multiple Myeloma Treatment Decisions
Amandeep Godara, MBBS, discusses how patient factors, disease burden, and logistics guide treatment decisions in relapsed/refractory multiple myeloma.
Addressing Biomarker Testing Gaps in NSCLC: Shiven B. Patel, MD, MBA
Shiven B. Patel, MD, MBA, discussed strategies for overcoming tissue limits, delays, and rural access gaps in NSCLC biomarker testing at an IVBM event.
Adaptive Trials Cut Time to Effective Breast Cancer Therapies: Laura Esserman, MD, MBA
Adaptive trials like I-SPY have lifted breast cancer complete response rates to 50%–60%, but better early end points are needed for wider use.
ADCs and Oral SERDs Reshape Breast Cancer Pharmacy Role: Tiffany Meng, PharmD
ADCs and oral SERDs are reshaping breast cancer care, easing toxicity but adding new sequencing, HER2 testing, and adherence challenges.
Adapting Breast Cancer Therapy to the Individual, Not Just the Scan: Lidia Schapira, MD
Lidia Schapira, MD, Stanford, urges care teams to weigh quality of life, not just scans, in long-term cancer therapy decisions.
Communication Is Key to Successful Cell Therapy Trials: Bridget Keenan, MD, PhD
Bridget Keenan, MD, PhD, of UCSF, stresses close communication across clinical, industry, and lab teams to run safe CAR T-cell trials.
CAR T, Bispecifics Reshape Relapsed Lymphoma Care: Madhav Seshadri, MD
CAR T remains Madhav Seshadri, MD's top pick for eligible relapsed/refractory DLBCL, though bispecific antibody regimens are viable alternatives.
Expanding Access to CAR T, Bispecific Therapies Requires System Changes: Peter Forsberg, MD
Peter Forsberg, MD, discusses why health systems must adapt to expand equitable access to CAR T-cell and bispecific therapies.